Enhancing
Organ TecHnology

We envision a future where preclinical experiments are conducted with utmost precision and efficiency, leveraging automation and scalability. Our goal is to create preclinical experiments that closely mimic the clinical reality of diseases, allowing for more accurate and reliable results.

We see organoid biology and medicine as a way to finding the best drug for each patient and  as organ replacement technology. By simplifying the way of generating these 3D structures we believe in rushing a highly patient-centric preclinical experiment era.

Present

The current drug discovery and development processes involve non-human disease models which lead to drug failures and patient suffering.

Future

We are striving to improve preclinical drug development by the production of physiologically relevant disease models that better replicate the human body.

The current drug discovery and development processes involve non-human disease models which lead to drug failures and patient suffering.

The current drug discovery and development processes involve non-human disease models which lead to drug failures and patient suffering.

We live
in a Patient-Centric
DISEASE MODEL World

Challenges
NORGANOID's solutions
1
Challenge
2D cell cultures can’t capture physiologically relevant tissue organisation. Although traditional cell culture is often featuring human cells, the main obstacle is the absence of hierarchical organization, cellular diversity, and interactions between cells and their environment. This preventscell lines to mimic cellular functions present in tissue. Therefore, the results obtained from 2D cell culture are not as predictive of clinical outcomes.
Approach
We see organoids and other 3D cell culture models as the next step after 2D-cell-based assays. By increasing the adoption of organoids in preclinical experiments we believe to increase the predictive power of the patient outcomes.
2
Challenge
Organoid culture is, however, a tedious process. Many protocols have a lot of moving parts and manual steps are required which increase the probability of failure.
Regulatory bodies require robust and reproducible data on preclinical experiments to accept first-in-human trials. Staying with traditional methods will likely continue to lead to failure.
Approach
Our NanoLab System™ (NLS™) is designed as a plug-and-play organ-on-chip (OoC) platform. NLS™ will handle everything from initial iPSC differentiation, to organoid culture and maintenance, and will be compatible with standard imaging systems.
3
Challenge
While liquid-handling robots offer automation of manual steps, using them for 3D cell culture leads to a large consumables spending and high variability in organoids.
OoC technology promises, increased in vitro model complexity but is linked to low experimental throughput and it is often limited to one organ per chip. Using in silico methods enables the fastest predictions and has the lowest cost per prediction but is not useful when used independently of other New Approach Methodologies (NAMs).
Approach
By integrating automated OoC technology with computer vision we aim to significantly increase the predictive power of drug and chemical safety screenings. Thereby we want to increase the adoption of organoids bring the pharma and biotech industry into the age of of patient-centric preclinical experiments.

Upcoming events

November 4, 2024
BIO-EUROPE 2024

Latest News

Subscribe to stay up to date!

NORGANOID GmbH